Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas[1].
Molecular Weight:
149000 (average)
Purity:
99.87
CAS Number:
[1642152-40-6]
Target:
Antibody-Drug Conjugates (ADCs)
Application Notes:
MCE Product type: ADC Related
* VAT and and shipping costs not included. Errors and price changes excepted